



PRIVILEGED AND CONFIDENTIAL: SUBJECT TO THE
ATTORNEY-CLIENT PRIVILEGE AND ATTORNEY
WORK PRODUCT DOCTRINE

RECEIVED
CENTRAL FAX CENTER

MAR 28 2005

March 28, 2005

VIA FAX:

703-872-9306

Examiner Rip A. Lee
Art Unit No. 1713


Subject: U.S. Patent Serial Number 10/679,217

Milliken file number 5646
MILLIKEN & COMPANY

**"IMPROVED NUCLEATING ADDITIVE FORMULATIONS OF BICYCLO
[2.2.1] HEPTANE DICARBOXYLATE SALTS**

Enclosed is a Response to the most recent Office Action.

Very truly yours,



John E. Vick, Jr.
Registration No. 33,808

MILLIKEN AND COMPANY
920 Milliken Road, M-495
Spartanburg, SC 29303
Telephone (864) 503-1383
Facsimile (864) 503-1999

Milliken & Company, P.O. Box 1928, Spartanburg, South Carolina 29304-1928, Telephone (864) 503-2020,
Facsimile (864) 503-1999

RECEIVED
CENTRAL FAX CENTER
MAR 28 2005

USPTO Customer No. 25280
Serial No: 10/679,217

Inventor(s): Mannion et al
Case No: 5646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mannion et al
Serial Number: 10/679,217
Filed: October 3, 2003
For:

Certificate of Facsimile Transmission	
I hereby certify that this correspondence, and all correspondence referenced herein as being enclosed with this correspondence, is being sent by fax to 703-872-9306	
date: 3/28/05	Name: <i>Julius</i>

**IMPROVED NUCLEATING ADDITIVE FORMULATIONS OF
BICYCLO[2.2.1]HEPTANE DICARBOXYLATE SALTS**

Group Art Unit: 1713
Examiner: Wu, David
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Amendment Under 37 CFR Section 1.116

This Amendment is submitted in response to the Office Action of January 31, 2005. This Amendment attends to relatively minor requirements of form only, and thus is believed to be appropriate for "after final" consideration pursuant to 1.116. Applicants therefore request consideration of this minor clarifying amendment.

Brackets shown in amended claim 5 are used to show the deletion of the "4", which is not readily apparent by the strike-through on the "4".